Susanna High
2023
In 2023, Susanna High earned a total compensation of $2M as Chief Operating Officer at Dyne Therapeutics, a 28% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $258,902 |
|---|---|
| Option Awards | $255,220 |
| Salary | $497,888 |
| Stock Awards | $1,032,436 |
| Other | $996 |
| Total | $2,045,442 |
High received $1M in stock awards, accounting for 50% of the total pay in 2023.
High also received $258.9K in non-equity incentive plan, $255.2K in option awards, $497.9K in salary and $996 in other compensation.
Rankings
In 2023, Susanna High's compensation ranked 513th out of 3,006 executives tracked by ExecPay. In other words, High earned more than 82.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 513 out of 3,006 | 83rd |
Division Manufacturing | 294 out of 1,650 | 82nd |
Major group Chemicals And Allied Products | 204 out of 918 | 78th |
Industry group Drugs | 201 out of 881 | 77th |
Industry Pharmaceutical Preparations | 127 out of 637 | 80th |
Source: SEC filing on April 5, 2024.
High's colleagues
We found two more compensation records of executives who worked with Susanna High at Dyne Therapeutics in 2023.
News
Dyne Therapeutics CEO Josh Brumm's 2023 pay jumps 38% to $6M
April 5, 2024
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021